PURPOSE: Therapy-related myelodysplasia or acute myelogenous leukemia (t-MDS/AML) is a lethal complication of autologous hematopoietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Here, we investigated the hypothesis that accelerated telomere shortening after aHCT could contribute to the development of t-MDS/AML. PATIENTS AND METHODS: A prospective longitudinal cohort was constructed to investigate the sequence of cellular and molecular abnormalities leading to development of t-MDS/AML after aHCT for HL/NHL. This cohort formed the sampling frame for a nested case-control study to compare changes in telomere length in serial blood samples from patients who developed t-MDS/AML with matched controls who did not develop t-MDS/AML. RESULTS: An initial increase in telomere length at day 100 after aHCT was followed by an accelerated telomere shortening in t-MDS/AML patients when compared with controls. These telomere alterations preceded the onset of t-MDS and were independent of other known risk factors associated with development of t-MDS/AML on multivariate analysis. Additionally, we observed reduced generation of committed progenitors in patients who developed t-MDS/AML, indicating that these telomere alterations were associated with reduced regenerative capacity of hematopoietic stem cells. CONCLUSION: The development of t-MDS/AML after aHCT is associated with and preceded by markedly altered telomere dynamics in hematopoietic cells. Accelerated telomere loss in patients developing t-MDS/AML may reflect increased clonal proliferation and/or altered telomere regulation in premalignant cells. Genetic instability associated with shortened telomeres may contribute to leukemic transformation in t-MDS/AML.
PURPOSE: Therapy-related myelodysplasia or acute myelogenous leukemia (t-MDS/AML) is a lethal complication of autologous hematopoietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Here, we investigated the hypothesis that accelerated telomere shortening after aHCT could contribute to the development of t-MDS/AML. PATIENTS AND METHODS: A prospective longitudinal cohort was constructed to investigate the sequence of cellular and molecular abnormalities leading to development of t-MDS/AML after aHCT for HL/NHL. This cohort formed the sampling frame for a nested case-control study to compare changes in telomere length in serial blood samples from patients who developed t-MDS/AML with matched controls who did not develop t-MDS/AML. RESULTS: An initial increase in telomere length at day 100 after aHCT was followed by an accelerated telomere shortening in t-MDS/AMLpatients when compared with controls. These telomere alterations preceded the onset of t-MDS and were independent of other known risk factors associated with development of t-MDS/AML on multivariate analysis. Additionally, we observed reduced generation of committed progenitors in patients who developed t-MDS/AML, indicating that these telomere alterations were associated with reduced regenerative capacity of hematopoietic stem cells. CONCLUSION: The development of t-MDS/AML after aHCT is associated with and preceded by markedly altered telomere dynamics in hematopoietic cells. Accelerated telomere loss in patients developing t-MDS/AML may reflect increased clonal proliferation and/or altered telomere regulation in premalignant cells. Genetic instability associated with shortened telomeres may contribute to leukemic transformation in t-MDS/AML.
Authors: R E Curtis; J D Boice; M Stovall; L Bernstein; R S Greenberg; J T Flannery; A G Schwartz; P Weyer; W C Moloney; R N Hoover Journal: N Engl J Med Date: 1992-06-25 Impact factor: 91.245
Authors: F E van Leeuwen; A M Chorus; A W van den Belt-Dusebout; A Hagenbeek; R Noyon; E H van Kerkhoff; H M Pinedo; R Somers Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: L B Travis; R E Curtis; B Glimelius; E Holowaty; F E Van Leeuwen; C F Lynch; J Adami; M Gospodarowicz; S Wacholder; P Inskip Journal: J Natl Cancer Inst Date: 1993-12-01 Impact factor: 13.506
Authors: D L Darrington; J M Vose; J R Anderson; P J Bierman; M R Bishop; W C Chan; M E Morris; E C Reed; W G Sanger; S R Tarantolo Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: R M Stone; D Neuberg; R Soiffer; T Takvorian; M Whelan; S N Rabinowe; J C Aster; P Leavitt; P Mauch; A S Freedman Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: Navneet S Majhail; Ruta Brazauskas; J Douglas Rizzo; Ronald M Sobecks; Zhiwei Wang; Mary M Horowitz; Brian Bolwell; John R Wingard; Gerard Socie Journal: Blood Date: 2010-10-06 Impact factor: 22.113
Authors: Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List Journal: Leuk Lymphoma Date: 2011-06-03
Authors: Kerri Nottage; Jennifer Lanctot; Zhenghong Li; Joseph P Neglia; Smita Bhatia; Sue Hammond; Wendy Leisenring; Anna Meadows; Deokumar Srivastava; Leslie L Robison; Gregory T Armstrong Journal: Blood Date: 2011-04-15 Impact factor: 22.113
Authors: Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2016-09-12 Impact factor: 5.742